152 related articles for article (PubMed ID: 36916531)
21. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer.
Kruger S; Haas M; Burger PJ; Ormanns S; Modest DP; Westphalen CB; Michl M; Kleespies A; Angele MK; Hartwig W; Bruns CJ; Niyazi M; Roeder F; Kirchner T; Werner J; Heinemann V; Boeck S
Pancreatology; 2016; 16(4):593-8. PubMed ID: 27067420
[TBL] [Abstract][Full Text] [Related]
22. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma.
Fukukura Y; Kumagae Y; Higashi R; Hakamada H; Nagano H; Hidaka S; Kamimura K; Maemura K; Arima S; Yoshiura T
Pancreatology; 2020 Sep; 20(6):1155-1163. PubMed ID: 32800574
[TBL] [Abstract][Full Text] [Related]
23. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study.
S D; L W; B GY; F YH; H SX; Q MZ; Hao C; W CQ; S LZ
World J Surg Oncol; 2017 Jul; 15(1):120. PubMed ID: 28673297
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma.
Otsuka H; Uemura K; Kondo N; Sumiyoshi T; Nakagawa N; Okada K; Seo S; Murakami Y; Takahashi S
Pancreatology; 2020 Oct; 20(7):1472-1478. PubMed ID: 32900632
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronan heterogeneity in pancreatic ductal adenocarcinoma: Primary tumors compared to sites of metastasis.
Placencio-Hickok VR; Lauzon M; Moshayedi N; Guan M; Kim S; Nissen N; Lo S; Pandol S; Larson BK; Gong J; Hendifar AE; Osipov A
Pancreatology; 2022 Jan; 22(1):92-97. PubMed ID: 34657790
[TBL] [Abstract][Full Text] [Related]
26. Is lung involvement a favorable prognostic factor for pancreatic ductal adenocarcinoma with synchronous liver metastases?-A propensity score analysis.
Ouyang H; Ma W; Jiang X; Gerdtsson AS; Liu D; Pan Z
Expert Rev Gastroenterol Hepatol; 2023 Apr; 17(4):405-412. PubMed ID: 36803208
[TBL] [Abstract][Full Text] [Related]
27. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.
Mashiko T; Nakano A; Masuoka Y; Yamamoto S; Ozawa S; Nakagohri T
BMC Surg; 2021 May; 21(1):237. PubMed ID: 33952223
[TBL] [Abstract][Full Text] [Related]
28. Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma.
Barrau M; Maoui K; Le Roy B; Roblin X; Mismetti P; Phelip JM; Williet N
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3447-3454. PubMed ID: 33715087
[TBL] [Abstract][Full Text] [Related]
29. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
30. Pathomorphological features of metastatic lymph nodes as predictors of postoperative prognosis in pancreatic cancer.
Hoshikawa M; Ogata S; Nishikawa M; Kimura A; Einama T; Noro T; Aosasa S; Hase K; Tsujimoto H; Ueno H; Yamamoto J
Medicine (Baltimore); 2019 Feb; 98(5):e14369. PubMed ID: 30702628
[TBL] [Abstract][Full Text] [Related]
31. Metastases or primary recurrence to the lung is related to improved survival of pancreatic cancer as compared to other sites of dissemination. Results of a systematic review with meta-analysis.
Guerra F; Barucca V; Coletta D
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1789-1794. PubMed ID: 32753117
[TBL] [Abstract][Full Text] [Related]
32. The impact of different metastatic patterns on survival in patients with pancreatic cancer.
He C; Huang X; Zhang Y; Lin X; Li S
Pancreatology; 2021 Apr; 21(3):556-563. PubMed ID: 33518454
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma.
Chen H; Xu Z; Shen Z; Weng Y; Wang W; Ying X; Wang X; Deng X; Shen B
Eur J Surg Oncol; 2022 May; 48(5):1062-1067. PubMed ID: 34887166
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer.
Stuart CM; Kirsch MJ; Zhuang Y; Meguid CL; Sugawara T; Colborn KL; Messersmith W; Lieu C; Gleisner AL; Del Chiaro M; Schulick RD; Meguid RA
Surgery; 2023 Sep; 174(3):654-659. PubMed ID: 37391327
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Evans TRJ; Van Cutsem E; Moore MJ; Bazin IS; Rosemurgy A; Bodoky G; Deplanque G; Harrison M; Melichar B; Pezet D; Elekes A; Rock E; Lin C; Strauss L; O'Dwyer PJ
Ann Oncol; 2017 Feb; 28(2):354-361. PubMed ID: 27998964
[TBL] [Abstract][Full Text] [Related]
36. Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma.
Pan X; Zhou J; Xiao Q; Fujiwara K; Zhang M; Mo G; Gong W; Zheng L
J Hematol Oncol; 2021 Nov; 14(1):184. PubMed ID: 34727952
[TBL] [Abstract][Full Text] [Related]
37. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
[TBL] [Abstract][Full Text] [Related]
38. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract][Full Text] [Related]
39. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.
Fu N; Qin K; Li J; Jin J; Jiang Y; Deng X; Shen B
Cancer Med; 2022 Sep; 11(18):3397-3406. PubMed ID: 35434972
[TBL] [Abstract][Full Text] [Related]
40. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma.
Jamiyan T; Shiraki T; Kurata Y; Ichinose M; Kubota K; Imai Y
World J Surg Oncol; 2020 Jun; 18(1):137. PubMed ID: 32571348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
